Predictive Factors for the Development of Dyspnea Within 7 Days After Admission Among Terminally Ill Cancer Patients

2021 ◽  
pp. 104990912110288
Author(s):  
Ryo Matsunuma ◽  
Takashi Yamaguchi ◽  
Masanori Mori ◽  
Tomoo Ikari ◽  
Kozue Suzuki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Predictive Factors ◽  
Performance Status ◽  
Univariate Analysis ◽  
Terminally Ill ◽  
Primary Lung Cancer ◽  
Poor Performance Status ◽  
Terminally Ill Cancer Patients ◽  
Development Group

Background: Predictive factors for the development of dyspnea have not been reported among terminally ill cancer patients. Objective: This current study aimed to identify the predictive factors attributed to the development of dyspnea within 7 days after admission among patients with cancer. Methods: This was a secondary analysis of a multicenter prospective observational study on the dying process among patients admitted in inpatient hospices/palliative care units. Patients were divided into 2 groups: those who developed dyspnea (development group) and those who did not (non-development group). To determine independent predictive factors, univariate and multivariate analyses using the logistic regression model were performed. Results: From January 2017 to December 2017, 1159 patients were included in this analysis. Univariate analysis showed that male participants, those with primary lung cancer, ascites, and Karnofsky Performance Status score (KPS) of ≤40, smokers, and benzodiazepine users were significantly higher in the development group. Multivariate analysis revealed that primary lung cancer (odds ratio [OR]: 2.80, 95% confidence interval [95% CI]: 1.47-5.31; p = 0.002), KPS score (≤40) (OR: 1.84, 95% CI: 1.02-3.31; p = 0.044), and presence of ascites (OR: 2.34, 95% CI: 1.36-4.02; p = 0.002) were independent predictive factors for the development of dyspnea. Conclusions: Lung cancer, poor performance status, and ascites may be predictive factors for the development of dyspnea among terminally ill cancer patients. However, further studies should be performed to validate these findings.

scholarly journals Palliative Performance Status, Heart Rate and Respiratory Rate as Predictive Factors of Survival Time in Terminally Ill Cancer Patients

2006 ◽  
Vol 31 (6) ◽  
pp. 485-492 ◽  
Author(s):  
Cristina de Miguel Sánchez ◽  
Sofía Garrido Elustondo ◽  
Alicia Estirado ◽  
Fernando Vicente Sánchez ◽  
Cristina García de la Rasilla Cooper ◽  
...  
Keyword(s):  
Heart Rate ◽  
Respiratory Rate ◽  
Survival Time ◽  
Cancer Patients ◽  
Predictive Factors ◽  
Performance Status ◽  
Terminally Ill ◽  
Terminally Ill Cancer Patients

scholarly journals Clinical Benefit of Chemotherapy for Small-Cell Lung Cancer Patients with Extremely Poor Performance Status (PS)

2018 ◽  
Vol 26 (1) ◽  
pp. 1-6
Author(s):  
Ou Yamaguchi ◽  
Hiroshi Kagamu ◽  
Atsuto Mouri ◽  
Ayako Shiono ◽  
Harue Utsugi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Clinical Benefit ◽  
Performance Status ◽  
Poor Performance ◽  
Small Cell ◽  
Poor Performance Status ◽  
Small Cell Lung ◽  
Lung Cancer Patients

scholarly journals Obtaining tissue diagnosis in lung cancer patients with poor performance status and its influence on treatment and survival

2017 ◽  
Vol 124 ◽  
pp. 30-35 ◽  
Author(s):  
John D. Maclay ◽  
John M.B. Farley ◽  
Colin McCowan ◽  
Conor Tweed ◽  
Robert Milroy
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Performance Status ◽  
Poor Performance ◽  
Poor Performance Status ◽  
Lung Cancer Patients ◽  
Tissue Diagnosis

scholarly journals Do Elderly Lung Cancer Patients Aged ≥75 Years Benefit from Immune Checkpoint Inhibitors?

Cancers ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 1995
Author(s):  
Nagio Takigawa ◽  
Nobuaki Ochi ◽  
Nozomu Nakagawa ◽  
Yasunari Nagasaki ◽  
Masataka Taoka ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Elderly Patients ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Performance Status ◽  
Small Cell ◽  
Poor Performance Status ◽  
Small Cell Lung ◽  
Lung Cancer Patients

Lung cancer patients ≥75 years represent nearly 40% of all lung cancer patients and continue to increase. If elderly patients have a good performance status and adequate organ function, they can be treated the same as non-elderly patients. However, few comparative studies limited to elderly patients (≥75 years) have been conducted. We review the evidence on using immune check inhibitors for the treatment of elderly patients (≥75 years old) with advanced non-small cell lung cancer. Prospective randomized or non-randomized, retrospective, registrational, insurance-based, and community-based studies have shown that elderly (≥75 years) and non-elderly patients are similarly treated with immune check inhibitors effectively and safely. However, such analyses have not shown that immune check inhibitors are significantly more effective than chemotherapy alone. In addition, patient selection might be critically performed to administer immune check inhibitors in the elderly because they are more likely to have a poor performance status with comorbidities, which lead to little benefit, even in non-elderly patients. There is a need for more evidence showing the benefit of immune check inhibitors in non-small cell lung cancer patients ≥75 years.

scholarly journals Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status

2020 ◽  
Vol 111 (10) ◽  
pp. 3739-3746
Author(s):  
Hirohisa Kano ◽  
Eiki Ichihara ◽  
Daijiro Harada ◽  
Koji Inoue ◽  
Hiroe Kayatani ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Performance Status ◽  
Poor Performance ◽  
Small Cell ◽  
Poor Performance Status ◽  
Small Cell Lung ◽  
Lung Cancer Patients

Effect of interval between diagnosis of advanced cancer and cessation of active anti-cancer treatment on survival in terminally ill cancer patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e20630-e20630
Author(s):  
Y. Kim ◽  
J. Lee ◽  
W. Choi ◽  
J. Park ◽  
H. Kim ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Cancer Treatment ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Performance Status ◽  
Terminally Ill ◽  
Time Interval ◽  
Terminally Ill Cancer Patients ◽  
Terminal Stage ◽  
Anti Cancer

e20630 Background: Although various prognostic factors have been proposed to predict survival in terminally ill cancer patients, accurate prognostication is still a challenging task for oncologists. The objective of this study was to evaluate whether the time interval between diagnosis of advanced cancer and cessation of active anti-cancer treatment (ATP; active treatment period) can predict survival in terminally ill cancer patients. Methods: We prospectively evaluated 79 patients with advanced (recurrent or metastatic) cancer who were determined as terminal stage, namely cessation of active anti-cancer treatment and transition to palliative care, by attending oncologists. ATP and other known prognostic factors including clinical symptoms and signs, performance status, laboratory tests, and clinical prediction of survival (CPS) were analyzed. Results: Of the 79 patients, 46 were male (58%) and 33 were female (42%) with a median age of 60 years (range, 21–82). Median overall survival after being diagnosed with advanced cancer was 11.6 months (95% confidence interval (CI), 8.02–15.18), and survival after being determined as terminal stage was 1.9 months (95% CI, 1.38–2.42). According to 3 ATP categories (< 3months, 3–12 months, and >12 months), terminal stage survival were 1.0 month, 1.8 months, and 3.6 months, respectively (p=0.002). On multivariate analysis, short ATP, non-colorectal cancer, fatigue, and Karnofsky performance status less than 50 were significantly associated with a poor prognosis. Conclusions: Our study suggests that ATP is an independent prognostic factor for survival in terminally ill cancer patients who cannot receive active anti-cancer treatment anymore. Future prognostic models should include ATP as a prognostic variable. No significant financial relationships to disclose.

Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers

Lung Cancer ◽  
2021 ◽  
Vol 152 ◽  
pp. 165-173
Author(s):  
Riccardo Lobefaro ◽  
Giuseppe Viscardi ◽  
Raimondo Di Liello ◽  
Giacomo Massa ◽  
Maria Lucia Iacovino ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Performance Status ◽  
Poor Performance ◽  
Small Cell ◽  
Inflammatory Biomarkers ◽  
Poor Performance Status ◽  
Small Cell Lung ◽  
Lung Cancer Patients

Factors Associated with Length of Survival among 1081 Terminally Ill Cancer Patients

1995 ◽  
Vol 11 (3) ◽  
pp. 20-24 ◽  
Author(s):  
Pierre Allard ◽  
Albert Dionne ◽  
Diane Potvin
Keyword(s):  
Palliative Care ◽  
Prognostic Factors ◽  
Survival Time ◽  
Cancer Patients ◽  
Performance Status ◽  
Terminally Ill ◽  
Patient Characteristics ◽  
Cancer Site ◽  
Primary Tumor Site ◽  
Terminally Ill Cancer Patients

To improve their ability to estimate the survival of terminally ill cancer patients, palliative care physicians require accurate information on prognostic factors. The objective of this study was to assess the extent to which variables such as patient characteristics and primary tumor site affect the length of survival of terminally ill cancer patients. The study population consisted of 1081 cancer patients admitted for terminal care to a 15-bed palliative care unit from 1985 to 1991. Univariate Kaplan-Meier survival analysis and multivariate Cox regression analyses were used to examine the relationship between patient characteristics at admission and survival time. The factor most strongly associated with shorter survival was poor performance status; this strong relationship was not altered by taking into account sex and primary cancer site in the multivariate analysis. For patients who were bedridden at admission, the death rate was 5.5 times higher (95% confidence interval (CI) 3.4–9.0) than that for ambulatory patients during the first four days of stay and it was 2.8 times higher (95% CI 2.0–3.9) subsequently (up to 19 days). The other prognostic factors significantly but slightly associated with poorer survival in the univariate analysis were primary lung cancer, male sex, and living with a spouse. These findings indicate that performance status is the main prognostic factor for accurately estimating the survival time of terminally ill cancer patients.

Sign in / Sign up

Export Citation Format

Share Document